—

Krystal Biotech Inc (KRYS) — the peer cohort

As of 2026-11-13 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Krystal Biotech Inc ranks 7 of 7 in its cohort on the Closelooknet composite (57/100) — the cohort is led by Halozyme Therapeutics Inc at 72/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
KRYS Krystal Biotech Inc 57 52 85 21 info 20.2%
HALO Halozyme Therapeutics Inc 72 73 94 49 info 25.2%
ONC BeOne Medicines AG 65 89 64 29 ok 1.9%
REGN Regeneron Pharmaceuticals Inc 65 87 72 46 neutral 4.1%
ARGX.BR Argen-X 64 79 75 25 ok 5%
UCB.BR UCB SA 64 75 71 42 info 1.6%
ARGX argenx NV ADR 63 71 74 25 ok 10.5%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-11-13

Quick answers

Who are Krystal Biotech Inc's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Halozyme Therapeutics Inc (HALO), BeOne Medicines AG (ONC), Regeneron Pharmaceuticals Inc (REGN), Argen-X (ARGX.BR), UCB SA (UCB.BR), argenx NV ADR (ARGX), as of 2026-11-13.

How does KRYS score against its peers?

Krystal Biotech Inc's composite reads 57/100, ranking 7 of 7 in its cohort as of 2026-11-13; the cohort's highest composite is Halozyme Therapeutics Inc at 72/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.